Novel therapeutic regimen have expanded the limited options for treatment of advanced prostate cancer (PCa) including 2nd generation AR signaling inhibitors [1–4], or taxane based chemotherapeutics [5, 6]. The gene discussed is AR; the disease is posterior cortical atrophy.